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Abstract 
Background: Due to their health condition, patients with neuromuscular diseases (NMD) are at greater risk of devel‑
oping serious complications with COVID‑19. The objective of this study was to analyze the prevalence of COVID‑19 
among NMD patients and the risk factors for its impact and severity during the first wave of the pandemic. Clinical 
data were collected from NMD‑COVID‑19 patients, between March 25, 2020 and May 11, 2020 in an anonymous sur‑
vey carried out by expert physicians from the French Health Care Network Filnemus.
Results: Physicians reported 84 patients, including: 34 with myasthenia gravis, 27 with myopathy and 23 with 
neuropathy. COVID‑19 had no effect on NMD for 48 (58%) patients and 48 (58%) patients developed low COVID‑19 
severity. COVID‑19 caused the death of 9 (11%) NMD patients. Diabetic patients were at greater risk of dying. Patients 
with diabetes, hypertension or severe forms of NMD had a higher risk of developing a moderate or severe form of 
COVID‑19. In our cohort, corticosteroids and other immunosuppressants were not significantly associated with higher 
COVID‑19 severity for acquired NMD.
Conclusion: During this period, a small percentage of French NMD patients was affected by COVID‑19 compared to 
the general French population and COVID‑19 had a limited short‑term effect on them. Diabetes, hypertension and a 
severe degree of NMD were identified as risk factors of unfavorable outcome following COVID‑19. Conversely, in our 
cohort of patients with acquired NMD, corticosteroids or other immunosuppressants did not appear to be risk factors 
for more severe COVID‑19.
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Background
Coronavirus-disease-2019 (COVID-19) is caused by 
coronavirus-2 (SARS-CoV-2). It quickly struck the entire 
world after its first appearance in China in December 
2019 and had catastrophic consequences on popula-
tions and health systems worldwide [1]. In France, pub-
lic health reports on September 21, 2021 declared that 
6  956  848 patients had been infected, causing 116  050 
deaths [2]. Although COVID-19 has great similarities to 
SARS and MERS, genome sequencing of SARS-CoV-2 
has revealed that it is a novel coronavirus [3]. COVID-
19 leads to a wide range of clinical signs including fever, 
fatigue, dry cough, headache, myalgia and anosmia [4, 5]. 
The symptoms and severity of COVID-19 depend on the 
patient’s age, health condition, sex and immune system 
[6].
In France, according to the National Data Bank of Rare 
Diseases (BNDMR), 50 000 patients suffer from neuro-
muscular diseases (NMD), a large group of rare diseases 
(300 forms listed to date) most often of genetic or auto-
immune origin which affect both children and adults. As 
they can be under immunosuppressive and/or immu-
nomodulator therapy, or subject to cardiac or respiratory 
failures, patients with NMDs are generally considered 
at high risk of developing serious complications with 
COVID-19 [6].
In 2014, the French Ministry of Health created the 
French Health Care Network for Rare NMDs named 
Filnemus (www. filne mus. fr). Filnemus is a structure with 
a vast territorial network comprising 71 expert centers 
[7]. The missions of Filnemus are to coordinate, promote 
and convene the various actions carried out in the field of 
rare NMDs.
Facing the COVID-19 public health emergency, the 71 
expert centers of Filnemus, in collaboration with patient 
organizations involved with NMD, set up a national 
observatory to enable the collection of data for NMD 
patients with COVID-19. This national multicenter 
study aimed to determine the prevalence of COVID-19 
for NMD patients and the risk factors for its impact and 
severity during the first French lockdown period.
Results
Cohort description
Data were collected from March 25, 2020 to May 11, 
2020 during the first lockdown period in France. During 
this period, 84 patients followed up in the expert centers 
and with a diagnosis of definite or probable COVID-19 
were reported by experts (Table 1). The cohort included 
34 patients with myasthenia gravis, 27 with myopathy 
and 23 with neuropathy (Table 1). No cases of COVID-19 
patients with spinal muscular atrophy were reported dur-
ing this period. The geographical distribution by region is 
shown in Fig. 1.
Twenty-eight patients had respiratory failure, 16 
patients had heart failure, 10 patients had diabetes, 11 
Table 1 Listing of neuromuscular diseases for patients with COVID‑19 (n number of patients)
Myasthenia n Myopathy n Neuropathy n
Autoimmune myasthenia gravis 32 Becker muscular dystrophy 1 Anti‑MAG neuropathy 1
Congenital myasthenic syndromes 2 Beta sarcoglycanopathy 1 Chronic Ataxic Neuropathy, Ophtamoplegia, IgM parapro‑
tein, cold Agglutinins and Disialosyl antibodies
1
Calpainopathy (LGMD2A) 3 Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome 1
Congenital muscular dystrophy 1 Charcot‑Marie‑Tooth disease 8
Congenital myotonia (Becker) 1 Chronic demyelinating inflammatory polyradiculoneuritis 4
Duchenne muscular dystrophy 3 Hereditary amyloid neuropathy 2
Gamma sarcoglycanopathy 1 Mitochondrial cytopathy 1
GNE myopathy 2 Multifocal motor neuropathy 2
Inclusion body myositis 1 Neuromyotonia 1





Type 1 myotonic dystrophy (Steinert) 4
Type 2 myotonic dystrophy (PROMM) 1
Type 3 glycogenosis 2
Unlabeled myopathy 1
34 27 23
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patients had high arterial blood pressure, 8 patients 
suffered from obesity and 19 patients were over 
65  years old (Table  2). The mean age of the patients 
was 50 years (range 18–94) and the female/male ratio 
was 1.47 (Table  2). The diagnosis of COVID-19 was 
established by PCR in 24 patients, based on thoracic 
CT-Scan results in 4 patients, by both PCR and tho-
racic CT-Scan in 20 patients, and by clinical signs 
highly suggestive of COVID-19 in 36 patients (Table 2). 
The prevalence of symptomatic COVID-19 was esti-
mated at 0.0017. The hospitalization rate in medical 
units and intensive care unit  (ICU) was respectively 
0.27 and 0.14. Forty-eight patients received home care.
Impact of COVID‑19 on NMD
For 48 (58%) NMD patients, COVID-19 had no effect on 
their pre-existing disease. COVID-19 caused worsening 
of symptoms in 26 (31%) NMD patients and death in 9 
(11%) NMD patients. The death rate was therefore 0.11. 
Of the 9 deaths recorded only 2 patients had a low severe 
neuromuscular disease, one of whom was diabetic and 
suffered from hypertension. Four out of 9 of deceased 
patients presented respiratory failure, 1/9 presented car-
diac failure, 5/9 presented diabetes, and 3/9 presented 
hypertension. Six out of 9 deceased patients presented 
at least two comorbidities such as respiratory or cardiac 
failure, hypertension, diabetes or being aged > 65  years. 
One patient was a 43-year-old man with myasthenia 
gravis and who presented no respiratory/cardiac failure, 
no comorbidity and a low degree of severity of neuro-
muscular disease. The cause of his death was acute res-
piratory distress syndrome.
Table  3 provides a description of the NMD cohort 
according to the impact of COVID-19 on NMD.
Univariate analysis revealed that obesity (p = 0.001) 
and diabetes (p < 0.001) were significantly associated with 
the exacerbation of NMD (Table 3).
Diabetes, along with gender (p = 0.079), hyperten-
sion (p = 0.097) and degree of mobility (p = 0.110) were 
included in a multinomial logistic regression (obesity was 
excluded due to small numbers, which were insufficient 
to enable the model to converge to a final solution). Res-
piratory failure was not significant (p = 0.233) but it is a 
risk factor known to influence the patient’s health condi-
tion following infection with SARS-CoV2 and was there-
fore included in the model. Compared to the reference 
category “without effect”, multinomial logistic regression 
showed that patients with diabetes (OR = 44.000; 95% CI 
4.821–401.548, p = 0.001) had a higher risk of death fol-
lowing COVID-19.
Concerning medication, statistical analysis performed 
only on the population suffering from acquired and not 
hereditary forms of NMD showed that corticosteroids or 
other immunosuppressants were not significantly associ-
ated with the impact of COVID-19 on NMD (p = 0.394 
and p = 0.565 respectively).
Impact of NMD on the severity of COVID‑19
For 48 (58%) NMD patients, the severity of COVID-19 
was low. Moderate COVID-19 severity was reported in 
23 (28%) NMD patients, while 12 (15%) NMD patients 
suffered from highly severe COVID-19. Table 4 provides 
a description of the NMD cohort according to the impact 
of NMD on the severity of COVID-19.
Univariate analyses showed that the severity of NMD 
(p = 0.007), high arterial blood pressure (p = 0.001), dia-
betes (p = 0.001), degree of mobility (p = 0.015) and 
gender (p = 0.031) were significantly associated with 
the degree of severity of COVID-19 for NMD patients 
(Table 4).
These variables, along with obesity (p = 0.097), 
age > 65  years (p = 0.070) and type of neuromus-
cular disease (p = 0.095) were included in a multi-
nomial logistic regression (except for respiratory 
failure due to small numbers, which were insufficient 
to enable the model to converge to a final solution). 
Compared to the reference category “low COVID-
19 severity”, multinomial logistic regression showed 
that patients with severe NMD (OR = 10.840; 95% CI 
1.888–62.255, p = 0.008) and patients with hyperten-
sion (OR = 15.511; 95% CI 1.526–157.619, p = 0.020) 
had a higher risk of developing moderate COVID-19 
Fig. 1 French geographical repartition of neuromuscular COVID‑19 
positive cases: size of red circle correspond to the number of 
neuromuscular COVID‑19 positive cases per French region (n number 
of cases per region)
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severity. In addition, patients with severe NMD 
(OR = 11.154; 95% CI 1.042–119.379, p = 0.046) and 
patients with diabetes (OR = 14.993; 95% CI 1.292–
174.014, p = 0.030) had a higher risk of developing 
high COVID-19 severity.
Concerning medication, statistical analysis of the 
population suffering from acquired and non-hered-
itary forms of NMD showed that corticosteroids and 
other immunosuppressants were not significantly 
associated with the degree of COVID-19 severity 
(p = 0.670 and p = 0.764 respectively).
Discussion
This multicenter study showed that 84 patients with 
NMD followed by the French expert centers network 
contracted COVID-19 during the period from March 25, 
2020 to May 11, 2020. Our cohort included 34 patients 
with myasthenia gravis, 23 with neuropathy and 27 with 
myopathy. COVID-19 caused an aggravation of their 
NMD in 26 (31%) patients and death in 9 (11%) patients. 
COVID-19 had no effect on 48 (58%) of them. Our study 
showed that the impact of COVID-19 on NMD did not 
depend on the category (neuropathy, myopathy and 
myasthenia gravis), acquired/hereditary nature of NMD 
or severity of NMD. Diabetic patients with NMD were 
at a greater risk of dying from COVID-19. In this cohort, 
COVID-19 severity was considered to be low in 48 (58%) 
NMD patients. Risk factors associated with the degree 
of COVID-19 severity were the severity of NMD, hyper-
tension and diabetes. In our cohort, corticosteroids and 
other immunosuppressants were not found to be factors 
associated with the degree of COVID-19 severity.
The state of health (cardio-respiratory failure, immu-
nosuppressive medication, and other comorbidities such 
as diabetes or hypertension) of patients suffering from 
NMD has caused increased fear of COVID-19 having a 
devastating impact on this population. Although signifi-
cant vigilance should be maintained, this fear was some-
what alleviated when we compared the data from this 
study with impact of COVID-19 on the general popula-
tion. Indeed, on May 11, 2020, in the context of the onset 
of a health crisis at a time when there were few PCR tests, 
France reported 178 719 positive cases including 26 646 
deaths, 19 572 people hospitalized in COVID-19 units 
and 2 712 in ICU [8]. The prevalence of COVID-19 in 
the population of NMD patients was therefore slightly 
lower than that of the French general population (0.0017 
for NMD patients versus 0.0026 for the general popula-
tion). The death rate in the NMD patient population was 
also lower than that of the French general population 
(0.11 vs. 0.14, respectively). However, the rate of hos-
pitalization in a medical unit and in ICU was higher in 
the NMD patient population than in the French general 
Table 2 Description of the cohort
n number of cases, No. (%) number of cases (% of cases)
Ɨ According to the physician
‡ Prior to COVID-19
§ Patients presenting clinical signs highly suggestive of COVID-19 (cough, fever, 
anosmia, hyposmia, skin signs, myalgia, headache, diarrhea, breathlessness, 
chest tightness)
Total (n = 84)
No. (%)
Age, years (mean ± SD) (min–max) 49.8 ± 18.70 (18–94)
Age > 65 years old 19 (22.9)
Gender (male) 34 (40.46)
Type of disease
 Myopathy 27 (40.5)
 Neuropathy 23 (27.4)
 Myasthenia 34 (40.5)
Origin of the disease
 Acquired 44 (53.0)
 Genetic 39 (47.0)
Severity of neuromuscular  diseaseƗ
 Low 30 (36.6)
 Moderate 36 (43.9)
 High 16 (19.5)
Mobility
 Walk 58 (70.7)
 Walk with help 12 (14.6)
 Wheelchair 12 (14.6)
Comorbidities
 Heart failure 16 (20.3)
 Respiratory failure 28 (35.9)
 Hypertension 11 (13.1)
 Diabetes 10 (11.9)
 Obesity 8 (9.5)
Medication‡
 Corticosteroids 14 (16.7)
 Other immunosuppressants 17 (20.2)
Diagnosis of COVID‑19
 PCR 24 (28.6)
 Thoracic CT‑Scan 4 (4.8)
 PCR + Thoracic CT‑Scan 20 (23.8)
 Neither § 36 (42.8)
Effect of COVID‑19
 Without 48 (57.8)
 Aggravating factor 26 (31.3)
 Death 9 (10.8)
Severity of COVID‑19
 Low 48 (57.8)
 Moderate 23 (27.7)
 High 12 (14.5)
Medical care
 Medical unit 23 (27.7)
 Intensive care unit 12 (14.5)
 Home care 48 (57.8)
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population (medical unit hospitalization: 0.27 for NMD 
patients, 0.14 for the general population; intensive care: 
0.14 for NMD patients, 0.019 for the general population). 
Interestingly, other epidemiological studies have been 
performed on French cohorts of patients with multiple 
sclerosis (MS) and patients with rheumatic and inflam-
matory diseases (iRMD) [9, 10]. In these diseases, the 
death rate was lower than in our study (3.5% for MS and 
8% for iRMD respectively, vs 11% in our cohort), simi-
larly to the hospitalization rate (21% for MS and 36% for 
iRMD respectively, vs. 42% in our cohort, medical unit 
and ICU). Other large epidemiological studies will be 
required to confirm these results.
Previous studies have reported that obesity, hyper-
tension, diabetes, gender, immunosuppressive drugs/
corticosteroids and age could be risk factors playing an 
important role in the evolution of COVID-19 in the gen-
eral population [4, 5, 11]. As expected, we found that 
the risk factors for the general population were identi-
fied as risk factors for the impact or degree of severity of 
COVID-19 in NMD patients. Interestingly, hypertension, 
gender and diabetes have also been recognized as com-
mon risk factors associated with COVID-19 severity in 
MS or iRMD cohorts [9, 10].
However, in our cohort of acquired NMD patients, ther-
apy with corticosteroids or other immunosuppressants 
Table 3 Impact of COVID‑19 on NMD
n number of cases, No. (%) number of cases (% of cases)
Ɨ According to the physician
‡ Prior to COVID-19
§ Statistical analysis have been performed only on populations with acquired disease
*p < 0.05 was statistically significant
Without effect (n = 48)
No. (%)
Aggravating factor (n = 26)
No. (%)
Death (n = 9)
No. (%)
p value
Type of disease 0.716
 Myopathy 17 (63) 8 (29.6) 2 (7.4)
 Neuropathy 15 (65.2) 6 (26.1) 2 (8.7)
 Myasthenia 16 (48.5) 12 (36.4) 5(15.2)
Origin of the disease 0.322
 Acquired 23 (53.5) 13 (30.2) 7 (16.3)
 Genetic 24 (61.5) 13 (33.3) 2 (5.1)
Severity of neuromuscular  diseaseƗ 0.170
 Low 21 (70.0) 7 (23.3) 2 (6.7)
 Moderate 19 (54.3) 13 (37.1) 3 (8.6)
 High 6 (37.5) 6 (37.5) 4 (25.0)
Mobility 0.110
 Walk 35 (61.4) 20 (35.1) 2 (3.5)
 Walk with help 7 (58.3) 3 (25.0) 2 (16.7)
 Wheelchair 6 (50.0) 3 (25.0) 3 (25.0)
Gender 0.079
 Men 15 (44.1) 13 (38.2) 6 (17.6)
 Women 33 (67.3) 13 (26.5) 3 (6.1)
Age > 65 yrs old 9 (47.4) 8 (42.1) 2 (10.5) 0.553
Respiratory failure 13 (48.1) 10 (37.0) 4 (14.8) 0.233
Heart failure 12 (75.0) 3 (18.8) 1 (6.2) 0.401
Obesity 0 7 (87.5) 1 (12.5) 0.001*
Hypertension 4 (36.4) 4 (36.4) 3 (27.3) 0.097
Diabetes 2 (20.0) 3 (30.0) 5 (50.0)  < 0.001*
Corticosteroids‡,§ 9 (69.2) 2 (15.4) 2 (15.4) 0.394
Immunosuppressants other than 
 corticosteroids‡,§
9 (60.0) 5 (33.3) 1 (6.7) 0.565
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did not appear to be risk factors for severe forms of 
COVID-19. In accordance with this, a study performed 
on 15 myasthenia gravis patients infected with COVID-
19 showed that immunosuppressive therapies did not 
seem to cause any additional unfavorable outcome [12]. 
Likewise, data from myasthenic patients in our cohort 
showed that corticosteroids or other immunosuppres-
sants used in the management of myasthenia gravis were 
not a risk factor for poorer outcomes [13]. However, 
studies performed on a cohort of 694 iRMD patients 
showed that long-term corticosteroid intake increased 
the risk of developing severe forms of COVID-19 [10]. 
The outcome of medication on COVID-19 severity could 
depend on doses, overlap between medications and/or 
timing between medication and infection. For these rea-
sons, results on corticosteroids/other immunosuppres-
sants should be interpreted with caution. Indeed, in our 
study, the sample size of NMD patients with COVID-19 
receiving corticosteroids/other immunosuppressants was 
small and cases were heterogeneous, concerning severity 
of the disease, type of pathology, type of drug adminis-
tered and doses. Currently, management of immunosup-
pressive/immune-modulator medication in this health 
crisis remains a challenge.
Similarly to scientific literature [14], our study showed 
that few patients with NMD contracted COVID-19 in 
France during this period. All of these results could 
be explained by patients paying particular attention to 
Table 4 Impact of NMD on COVID‑19
n number of cases, No. (%) number of cases (% of cases)
Ɨ According to the physician
‡ Prior to COVID-19
§ Statistical analysis have been performed only on populations with acquired diseases
*p < 0.05 was statistically significant
Low COVID‑19 severity 
(n = 48)
No. (%)
Moderate COVID‑19 severity 
(n = 23)
No. (%)




Type of disease 0.095
 Myopathy 16 (59.3) 8 (29.6) 3 (11.1)
 Neuropathy 12 (52.2) 10 (43.5) 1 (4.3)
 Myasthenia 20 (60.6) 5 (15.2) 8 (24.2)
Origin of the disease 0.199
 Acquired 24 (55.8) 10 (23.3) 9 (20.9)
 Genetic 23 (59.0) 13 (33.3) 3 (7.7)
Severity of neuromuscular  diseaseƗ 0.007*
 Low 21 (72.4) 6 (20.7) 2 (6.9)
 Moderate 22 (61.1) 8 (22.2) 6 (16.7)
 High 3 (18.8) 9 (56.2) 4 (25.0)
Mobility 0.015*
 Walk 40 (70.2) 12 (21.1) 5 (8.8)
 Walk with help 5 (41.7) 4 (33.3) 3 (25.0)
 Wheelchair 3 (25.0) 6 (50.0) 3 (25.0)
Gender 0.031*
 Men 14 (41.2) 14 (41.2) 6 (17.6)
 Women 34 (69.4) 9 (18.4) 6 (12.2)
Age > 65 yrs old 9 (47.4) 9 (47.4) 1 (5.3) 0.070
Respiratory failure 12 (42.9) 10 (35.7) 6 (21.4) 0.079
Heart failure 8 (50.0) 6 (37.5) 2 (12.5) 0.617
Obesity 2 (25.0) 4 (50.0) 2 (25.0) 0.097
Hypertension 1 (9.1) 7 (63.6) 3 (27.3) 0.001*
Diabetes 1 (10.0) 4 (40.0) 5 (50.0) 0.001*
Corticosteroids‡,§ 6 (46.2) 4 (30.8) 3 (23.1) 0.670
Immunosuppressants other than 
 corticosteroids‡,§
8 (50.0) 4 (25.0) 4 (25.0) 0.764
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self-isolation and hygiene measures, working from home 
more often and actions carried out by neuromuscular 
patient organizations and Filnemus, whose ambition dur-
ing this public health crisis was to fight this virus and to 
protect patients with neuromuscular diseases. Nonethe-
less, one of major deleterious impacts of COVID-19 is 
that the health crisis has had huge consequences on the 
management of NMD patients [14–16]. Several patients 
have foregone or did not have access to medical care 
and have developed more stiffness, more pain or have 
reduced their walking distance.
In the context of an emergency health crisis, this 
dynamic observatory of the number and state of health 
of patients has enabled Filnemus to directly monitor the 
evolution of this virus in patients with NMDs. Know-
ing the evolution and the impact of this virus on NMD 
patients enabled Filnemus to draw up a document 
intended to help resuscitators in their decision-making, 
in order to provide equal opportunities for the manage-
ment of patients with NMD in intensive care. The data 
collected in this survey is essential to understand the 
impact of COVID-19 on this population but remains 
insufficient. Although our method of data collection was 
effective it was not exhaustive. One of the limitations of 
our study is the lack of confirmation of COVID-19 for 
several patients in our cohort due to a lack of testing 
at that time. Indeed, many cases with symptoms sug-
gestive of COVID-19 could not be confirmed by PCR 
test or Thoracic CT-scan and asymptomatic cases were 
not detected. Although the clinical diagnosis allowing 
patients to be included in the cohort is based on very 
specific criteria published in major scientific journals 
and which are highly suggestive of COVID-19, additional 
studies will help deepen knowledge on this subject and 
clarify the impact of this virus on various NMDs.
The aim of this study was to evaluate the consequences 
of COVID-19 on NMD patients in the short term. Based 
on our results we cannot exclude that the effects of 
COVID-19 on these patients could appear in the longer 
term. It would be interesting to investigate this as a sec-
ond step.
To conclude, this French multicenter study shows that 
few patients with NMDs presented symptoms of and/or 
tested positive for COVID-19 during this first lockdown 
period. COVID-19 in patients with NMD did not sys-
tematically lead to NMD aggravation and severe forms of 
COVID-19. Diabetes is a risk factor for unfavorable out-
come for NMD − COVID-19 + patients. The severity of 
COVID-19 for NMD patients depended on the degree of 
NMD severity, diabetes and hypertension. Finally, in this 
cohort, treatment with corticosteroids or other immu-
nosuppressants was not associated with higher COVID-
19 severity. As a whole, these results should help adapt 
the management of neuromuscular patients during the 
COVID-19 pandemic and also the prioritization and 




Data was collected in real time by physicians from 71 
expert centers belonging to Filnemus. Expert centers 
and patient organizations made calls to 18 000 NMD 
patients to ensure their good health. Patients presenting 
COVID-19 clinical symptoms were encouraged to con-
tact their physician. The survey was performed during 
the first French lockdown period that lasted from March 
25, 2020 to May 11, 2020. This anonymous study was car-
ried out in accordance with good clinical practice, Gen-
eral Data Protection Regulations (GDPR) and the local 
ethics committee. Patients included in this study were 
informed by their physician who signed informed con-
sent notes of non-objection. All the patients in this study 
had NMD and were strongly suspected to be infected by 
SARS-CoV2. COVID-19 was confirmed either by PCR, 
or suspected by thoracic computed tomography (thoracic 
CT-Scan) [17] or symptomatology including several asso-
ciated signs suggesting COVID-19: cough, fever, hypos-
mia, skin manifestations, myalgia, headache, diarrhea, 
breathlessness, chest tightness and anosmia. At this time 
in the pandemic PCR testing was not performed sys-
tematically. Patients with clinical signs highly suggestive 
of COVID-19 but without positive PCR or thoracic CT-
Scan results were considered to be probable cases.
Variables studied
Data collected prior to COVID-19 were: age, gender, 
diagnosis, acquired/hereditary form of disease, degree of 
mobility (walking without help, walking with help or in 
a wheelchair), comorbidities, presence of respiratory (yes 
or no) or cardiac (yes or no) failure, degree of severity of 
the NMD according to the physician (low, moderate or 
severe) and medication. Categorization of the severity 
of patients’ neuromuscular disease was discussed during 
the Filnemus COVID-19 meetings that have been held 
weekly since the beginning of the pandemic and a con-
sensus was reached.
Data related to COVID-19 were: diagnosis of COVID-
19 (PCR/thoracic CT-Scan or clinical diagnostic criteria), 
impact of COVID-19 on the disease (no effect, aggra-
vating factor, or death), and categories of medical care 
(home care, medical unit, ICU). The severity of COVID-
19 was considered low for patients with home care, mod-
erate for patients needing hospitalization in a medical 
unit and high for patients hospitalized in ICU.
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The hospitalization rate was the ratio of NMD patients 
hospitalized in a medical unit over the total number of 
patients infected by SARS-CoV2 virus. The ICU rate 
was determined by the number of NMD patients hos-
pitalized in ICU divided by the total number of NMD 
patients infected by SARS-CoV2 virus. The death rate 
was calculated as the number of NMD patients dying 
after SARS-CoV2 infection divided by the total number 
of NMD patients infected by SARS-CoV2. The preva-
lence of COVID-19 in the NMD population was defined 
as the number of NMD patients infected by SARS-CoV2 
divided by the total number of NMD patients in France.
Outcomes
The primary endpoint was the impact of COVID-19 on 
NMD. The effect of COVID-19 was classified into three 
levels according to the physician’s evaluation: no effect, 
aggravating factor, death. The secondary endpoint was 
the impact of NMD on COVID-19 severity. COVID-
19 severity was assessed and classified according to the 
medical care received by each patient: low COVID-
19 severity = home care, moderate COVID-19 sever-
ity = hospitalization in a medical unit, high COVID-19 
severity = hospitalization in ICU.
Statistical analysis
The basic characteristics of the cohort were summarized 
as frequencies and percentages for categorical variables 
and were expressed as mean ± standard deviation for 
normally distributed continuous variables.
Univariate and multivariate analyses were performed 
on the cohort. First, in the univariate analysis, risk fac-
tors were assessed using analysis of variance (ANOVA) 
to compare continuous variables across groups, and Chi-
square test or Fisher-Freeman-Halton’s exact test were 
used for categorical variables, as appropriate. Second, 
two stepwise multinomial logistic regressions were used 
for the multivariate analysis by selecting all variables with 
a p-value not exceeding 0.15 in the univariate analysis 
to determine the independent risk factors for the effect 
of COVID-19 on NMD (Model 1, "no effect" reference 
category) and for the effect of NMD on the severity of 
COVID-19 (Model 2, “low COVID-19 severity” reference 
category). Odds ratios (OR) with their associated 95% 
confidence intervals (CI) were reported. A p-value < 0.05 
was considered statistically significant. All statistical 
analyses were performed using SPSS software, version 
20.0 (SPSS, Inc., Chicago, Illinois).
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